

Pertuzumab APHINITY


Pertuzumab APHINITY

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



QoL data pending



#### Serious and disabling adverse effects



#### Other adjustments



### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Therapeutic Indication: Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (node-positive or hormone receptor-negative disease)

Experimental Arm: Pertuzumab + Standard adjuvant ChT + 1 year of treatment with trastuzumab

Control Arm: Placebo + standard adjuvant ChT + 1 year of treatment with trastuzumab



